Lung cancer biomarkers

present status and future developments.

Philip T. Cagle, Timothy Craig Allen, Randall J. Olsen

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.

Original languageEnglish (US)
Pages (from-to)1191-1198
Number of pages8
JournalArchives of pathology & laboratory medicine
Volume137
Issue number9
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Tumor Biomarkers
Lung Neoplasms
Biomarkers
Guidelines
Protein-Tyrosine Kinases
Precision Medicine
Molecular Pathology
Cost-Benefit Analysis
Publications
Technology
Pharmaceutical Preparations
Pathologists

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lung cancer biomarkers : present status and future developments. / Cagle, Philip T.; Allen, Timothy Craig; Olsen, Randall J.

In: Archives of pathology & laboratory medicine, Vol. 137, No. 9, 09.2013, p. 1191-1198.

Research output: Contribution to journalArticle

Cagle, Philip T. ; Allen, Timothy Craig ; Olsen, Randall J. / Lung cancer biomarkers : present status and future developments. In: Archives of pathology & laboratory medicine. 2013 ; Vol. 137, No. 9. pp. 1191-1198.
@article{fab3a86eea5a4998bfbccb7ec1002d4f,
title = "Lung cancer biomarkers: present status and future developments.",
abstract = "The publication of the {"}Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology{"} has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.",
author = "Cagle, {Philip T.} and Allen, {Timothy Craig} and Olsen, {Randall J.}",
year = "2013",
month = "9",
doi = "10.5858/arpa.2013-0319-CR",
language = "English (US)",
volume = "137",
pages = "1191--1198",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "9",

}

TY - JOUR

T1 - Lung cancer biomarkers

T2 - present status and future developments.

AU - Cagle, Philip T.

AU - Allen, Timothy Craig

AU - Olsen, Randall J.

PY - 2013/9

Y1 - 2013/9

N2 - The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.

AB - The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.

UR - http://www.scopus.com/inward/record.url?scp=84887556493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887556493&partnerID=8YFLogxK

U2 - 10.5858/arpa.2013-0319-CR

DO - 10.5858/arpa.2013-0319-CR

M3 - Article

VL - 137

SP - 1191

EP - 1198

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 9

ER -